| Extension of the Period Before the Food and Drug Administration Intends To Begin Enforcing the Statutory 5 Percent Limit on Out of State Distribution of Compounded Human Drug Products |
FR |
| Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials; Guidance for Industry; Availability |
FR |
| Development and Submission of Near Infrared Analytical Procedures; Guidance for Industry; Availability |
FR |
| Genus Medical Technologies LLC Versus Food and Drug Administration; Request for Information and Comments |
FR |